TITLE:
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

CONDITION:
HIV Infections

INTERVENTION:
Tenofovir disoproxil fumarate

SUMMARY:

      This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil
      fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the
      drug causes.
    

DETAILED DESCRIPTION:

      HIV-1-infected patients who are currently receiving stable antiretroviral therapy add
      tenofovir DF to their regimen. Study participation lasts for approximately 48 weeks.
      Interested patients should contact their physicians.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        You may be eligible for this study if you:

          -  Are HIV-positive.

          -  Have a viral load greater than or equal to 10,000 copies/ml.

          -  Have a CD4 count less than or equal to 50 cells/mm3, or have a CD4 count greater than
             50 and no more than 200 cells/mm3 with an opportunistic (AIDS-related) infection
             within 90 days of study entry. (Patients with a CD4 count above 200 cells/mm3 may be
             considered depending on drug supply.)

          -  Are at least 18 years old.

          -  Agree to use barrier methods of birth control (such as condoms) while on the study
             and for 30 days afterward.

          -  Have a life expectancy of at least one year.

        Exclusion Criteria

        You will not be eligible for this study if you:

          -  Have a history of a serious kidney or bone disease.

          -  Have severe nausea, vomiting, or trouble taking medications by mouth.

          -  Are pregnant or breast-feeding.

          -  Abuse alcohol or other substances that your doctor thinks would interfere with taking
             this medicine.

          -  Are taking any medicines that interfere with kidney functions.
      
